IS THERE A RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) POST-DOCETAXEL?

被引：2
|
作者：
Traina, S. [1 ]
Li, T. [1 ]
Johnson, K. [1 ]
Ho, K. F. [2 ]
Molina, A. [3 ]
Cella, D. [4 ]
机构：
[1] Janssen Res & Dev, Raritan, NJ USA
[2] STAT TU Inc, Toronto, ON, Canada
[3] Janssen Res & Dev, Menlo Pk, CA USA
[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1244
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN226
引用
收藏
页码：A470 / A470
页数：1
相关论文
共 50 条
  • [31] Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial
    Sonpavde, Guru
    Pond, Gregory Russell
    Clarke, Stephen John
    Vardy, Janette L.
    Wang, S. L.
    Paolini, Jolanda
    Lechuga, Mariajose
    Michaelson, M. Dror
    Smith, Matthew Raymond
    Chen, Isan
    Maneval, Edna Chow
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] TREATMENT SEQUENCES, PATIENT CHARACTERISTICS, AND OVERALL SURVIVAL OF PATIENTS WITH POST-DOCETAXEL METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN THE COMMUNITY SETTING
    Oh, W. K.
    Miao, R.
    Duh, M. S.
    Vekeman, F.
    Sung, J.
    Cheng, W. Y.
    Gauthier-Loiselle, M.
    Fortier, J.
    Dhawan, R.
    VALUE IN HEALTH, 2016, 19 (03) : A139 - A139
  • [33] Patient characteristic, treatment and outcomes in metastatic Castration Resistant Prostate Cancer (mCRPC) in Finland
    Rannikko, A. S.
    Agesen, T.
    Holsa, O.
    Tuominen, S.
    Hanssen, J.
    Mattila, R.
    EUROPEAN UROLOGY, 2023, 83
  • [34] Plasma circulating tumor DNA (ctDNA) based clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
    Kohli, Manish
    Tan, Winston
    Zheng, Tiantian
    Wang, Amy
    Huo, Yelia
    Montesinos, Carlos
    Wong, Calvin
    Du, Pan
    Jia, Shidong
    Yu, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [35] Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and atrasentan versus docetaxel and placebo in a randomized phase iii clinical trial (Swog s0421)
    Unger J.M.
    Griffin K.
    Donaldson G.W.
    Baranowski K.M.
    Good M.J.
    Reburiano E.
    Hussain M.
    Monk P.J.
    Van Veldhuizen P.J.
    Carducci M.A.
    Higano C.S.
    Lara P.N.
    Tangen C.M.
    Quinn D.I.
    Wade J.L., III
    Vogelzang N.J.
    Thompson I.M., Jr.
    Moinpour C.M.
    Journal of Patient-Reported Outcomes, 2 (1)
  • [36] Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa
    Bassi, Sunakshi
    Schweizer, Michael Thomas
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [37] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Bilusic, Marijo
    Karzai, Fatima
    Cordes, Lisa M.
    Strauss, Julius
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Karzai, Fatima
    Cordes, Lisa M.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [39] Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes
    Boccardo, F.
    Cavo, A.
    Zanardi, E.
    Fabbroni, C.
    Zinoli, L.
    Di Meglio, A.
    Arboscello, E.
    Bellodi, A.
    Spallarossa, P.
    Cattrini, C.
    Messina, C.
    Rubagotti, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
    Caffo, O.
    Biasco, E.
    Facchini, G.
    Fratino, L.
    Gasparro, D.
    Mosillo, C.
    Maruzzo, M.
    Santini, D.
    Tucci, M.
    Ortega, C.
    Verderame, F.
    Scagliarini, S.
    Lo Re, G.
    Procopio, G.
    Fornarini, G.
    Campadelli, E.
    Sabbatini, R.
    Maines, F.
    De Giorgi, U.
    ANNALS OF ONCOLOGY, 2016, 27
12345